Skip to content

An Exploratory Study on the Use of Handheld Real-time Live Cell Scanner to Observe the Extent of Glioma Resection

An Exploratory Study on the Use of Handheld Real-time Live Cell Scanner to Observe the Extent of Glioma Resection

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2500101224
Enrollment
Unknown
Registered
2025-04-22
Start date
2023-05-26
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glioma

Interventions

Observation group:None

Sponsors

Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 85 Years

Inclusion criteria

Inclusion criteria: 1.Patients with gliomas confirmed by cranial magnetic resonance imaging and undergoing surgical treatment; 2.Aged between 18 and 85 years old; 3.Willing to cooperate and complete the study follow-up and related examinations; 4.Signed the informed consent form after being fully informed.

Exclusion criteria

Exclusion criteria: 1.Patients with severe cardiovascular or circulatory system diseases who cannot tolerate surgery; 2.Patients who have participated in other investigational drug or device clinical trials within the past 3 months; 3.Patients who cannot understand the requirements of the trial or cannot complete the study follow-up plan; 4.Pregnant patients; 5.Patients whom the investigator deems to have other conditions unsuitable for enrollment.

Design outcomes

Primary

MeasureTime frame
Effectiveness: Comparison of consistency with tissue section staining;

Secondary

MeasureTime frame
Safety;

Countries

China

Contacts

Public ContactYongping You

Jiangsu Province Hospital (The First Affiliated Hospital with Nanjing Medical University)

yypl9@njmu.edu.cn+86 25 68306360

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026